HRP20180049T1 - Derivati diazakarbazola kao tau-pet ligandi - Google Patents

Derivati diazakarbazola kao tau-pet ligandi Download PDF

Info

Publication number
HRP20180049T1
HRP20180049T1 HRP20180049TT HRP20180049T HRP20180049T1 HR P20180049 T1 HRP20180049 T1 HR P20180049T1 HR P20180049T T HRP20180049T T HR P20180049TT HR P20180049 T HRP20180049 T HR P20180049T HR P20180049 T1 HRP20180049 T1 HR P20180049T1
Authority
HR
Croatia
Prior art keywords
formula
compound
image
tau
compounds
Prior art date
Application number
HRP20180049TT
Other languages
English (en)
Croatian (hr)
Inventor
Luca Gobbi
Henner Knust
Matthias Koerner
Dieter MURI
Original Assignee
F. Hoffmann - La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann - La Roche Ag filed Critical F. Hoffmann - La Roche Ag
Publication of HRP20180049T1 publication Critical patent/HRP20180049T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/2814Dementia; Cognitive disorders
    • G01N2800/2821Alzheimer

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HRP20180049TT 2013-10-08 2014-10-06 Derivati diazakarbazola kao tau-pet ligandi HRP20180049T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13187764 2013-10-08
PCT/EP2014/071283 WO2015052105A1 (en) 2013-10-08 2014-10-06 Diazacarbazole derivatives as tau-pet-ligands
EP14781169.9A EP3055308B1 (en) 2013-10-08 2014-10-06 Diazacarbazole derivatives as tau-pet-ligands

Publications (1)

Publication Number Publication Date
HRP20180049T1 true HRP20180049T1 (hr) 2018-02-09

Family

ID=49301396

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180049TT HRP20180049T1 (hr) 2013-10-08 2014-10-06 Derivati diazakarbazola kao tau-pet ligandi

Country Status (32)

Country Link
US (2) US10004817B2 (enExample)
EP (1) EP3055308B1 (enExample)
JP (1) JP6194416B2 (enExample)
KR (1) KR101770531B1 (enExample)
CN (1) CN105358558B (enExample)
AR (1) AR097931A1 (enExample)
AU (1) AU2014333996B2 (enExample)
CA (1) CA2917191C (enExample)
CL (1) CL2016000728A1 (enExample)
CR (1) CR20150663A (enExample)
DK (1) DK3055308T3 (enExample)
EA (1) EA028483B1 (enExample)
ES (1) ES2657121T3 (enExample)
HR (1) HRP20180049T1 (enExample)
HU (1) HUE035413T2 (enExample)
IL (1) IL243249A0 (enExample)
LT (1) LT3055308T (enExample)
MA (1) MA38935B1 (enExample)
MX (1) MX373153B (enExample)
MY (1) MY190196A (enExample)
NO (1) NO3055308T3 (enExample)
PE (1) PE20160159A1 (enExample)
PH (1) PH12016500249B1 (enExample)
PL (1) PL3055308T3 (enExample)
PT (1) PT3055308T (enExample)
RS (1) RS56777B1 (enExample)
SG (1) SG11201602786UA (enExample)
SI (1) SI3055308T1 (enExample)
TW (1) TWI513698B (enExample)
UA (1) UA116164C2 (enExample)
WO (1) WO2015052105A1 (enExample)
ZA (1) ZA201509013B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100135235A (ko) 2008-02-14 2010-12-24 지멘스 메디컬 솔루션즈 유에스에이, 인크. 신경학적 기능이상을 검출하기 위한 조영제
NO3055308T3 (enExample) 2013-10-08 2018-04-21
PT3143011T (pt) 2014-05-13 2021-04-26 Hoffmann La Roche Compostos heterocíclicos deuterados e a sua utilização como agentes de imagiologia
ES2875734T3 (es) 2015-02-02 2021-11-11 UCB Biopharma SRL Derivados de 9H-pirrolo-dipiridina
EP3118202A1 (en) 2015-07-15 2017-01-18 AC Immune S.A. Dihydropyridopyrrole derivatives as tau-pet-ligands
WO2017009454A1 (en) 2015-07-15 2017-01-19 Ac Immune S.A. Novel imaging compounds
MX386900B (es) 2016-07-22 2025-03-19 Ac Immune S A Star Compuestos para formacion de imagenes de agregados de proteinas tau.
WO2018015546A1 (en) 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
WO2018024643A1 (en) 2016-08-02 2018-02-08 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
WO2018024642A1 (en) 2016-08-02 2018-02-08 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
MX375720B (es) 2016-09-09 2025-03-04 Hoffmann La Roche Proceso para preparacion de 2-(6-nitropiridin-3-il)-9h-dipirido[2,3-beta;3',4'-d]pirrol.
JP7260552B2 (ja) * 2018-01-24 2023-04-18 エーシー・イミューン・エス・アー Pet画像化のための診断用組成物、診断用組成物を製造するための方法及び診断におけるその使用
KR20200113234A (ko) 2018-01-24 2020-10-06 에이씨 이뮨 에스.에이. 이미징 화합물을 제조하는 신규한 방법
EP3743423A1 (en) 2018-01-24 2020-12-02 AC Immune SA Gamma-carboline compounds for the detection of tau aggregates
EP3743426A1 (en) 2018-01-24 2020-12-02 AC Immune SA Azacarboline compounds for the detection of tau aggregates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100135235A (ko) 2008-02-14 2010-12-24 지멘스 메디컬 솔루션즈 유에스에이, 인크. 신경학적 기능이상을 검출하기 위한 조영제
US8932557B2 (en) * 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
BRPI0909957A2 (pt) 2008-06-11 2016-04-19 Genentech Inc "composto, composição farmacêutica, método de inibir o crescimento anormal de células ou de tratar um distúrbio hiperproliferativo em um mamífero, método de tratamento do câncer em um mamífero"
US8420052B2 (en) * 2008-07-24 2013-04-16 Siemens Medical Solutions Usa, Inc. Imaging agents useful for identifying AD pathology
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
CN102438660A (zh) * 2009-03-23 2012-05-02 美国西门子医疗解决公司 用于检测神经障碍的显像剂
US20110183938A1 (en) 2009-12-16 2011-07-28 Genentech, Inc. 1,7-diazacarbazoles and methods of use
US20150368244A1 (en) * 2011-01-31 2015-12-24 Genentech, Inc. Diazacarbazoles and methods of use
NO3055308T3 (enExample) * 2013-10-08 2018-04-21

Also Published As

Publication number Publication date
DK3055308T3 (en) 2018-01-22
MA38935A1 (fr) 2016-04-29
PL3055308T3 (pl) 2018-03-30
US20180326099A1 (en) 2018-11-15
PE20160159A1 (es) 2016-03-18
US10004817B2 (en) 2018-06-26
CA2917191A1 (en) 2015-04-16
AR097931A1 (es) 2016-04-20
CL2016000728A1 (es) 2016-11-11
AU2014333996B2 (en) 2018-03-15
KR20160047552A (ko) 2016-05-02
HUE035413T2 (en) 2018-05-02
NO3055308T3 (enExample) 2018-04-21
ES2657121T3 (es) 2018-03-01
KR101770531B1 (ko) 2017-08-22
LT3055308T (lt) 2018-02-12
EP3055308A1 (en) 2016-08-17
IL243249A0 (en) 2016-02-29
TWI513698B (zh) 2015-12-21
CA2917191C (en) 2021-08-10
MX2016002234A (es) 2016-06-06
PT3055308T (pt) 2018-01-18
MY190196A (en) 2022-04-04
EA028483B1 (ru) 2017-11-30
HK1215574A1 (zh) 2016-09-02
JP6194416B2 (ja) 2017-09-06
UA116164C2 (uk) 2018-02-12
EA201690515A1 (ru) 2016-07-29
JP2016534979A (ja) 2016-11-10
PH12016500249A1 (en) 2016-05-16
US11058781B2 (en) 2021-07-13
CR20150663A (es) 2016-01-27
MX373153B (es) 2020-04-21
TW201520212A (zh) 2015-06-01
CN105358558B (zh) 2017-09-26
US20160220712A1 (en) 2016-08-04
CN105358558A (zh) 2016-02-24
ZA201509013B (en) 2016-10-26
EP3055308B1 (en) 2017-11-22
WO2015052105A1 (en) 2015-04-16
MA38935B1 (fr) 2016-12-30
SI3055308T1 (en) 2018-03-30
NZ714831A (en) 2021-09-24
RS56777B1 (sr) 2018-04-30
SG11201602786UA (en) 2016-05-30
PH12016500249B1 (en) 2016-05-16
AU2014333996A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
HRP20180049T1 (hr) Derivati diazakarbazola kao tau-pet ligandi
HRP20201984T1 (hr) Priprema (s)-n-(5-((r)-2-(2,5-difluorofenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
HRP20200666T1 (hr) Derivati piridin-2(1h)-on kinolinona kao inhibitori mutirane izocitrat dehidrogenaze
HRP20201480T1 (hr) Derivati indolinona i postupak za njihovu proizvodnju
Wickstrøm et al. The development of an automated and GMP compliant FASTlab™ Synthesis of [18F] GE‐180; a radiotracer for imaging translocator protein (TSPO)
SG188444A1 (en) Method for rapid preparation of suitable [18f]fluoride for nucleophilic [18f]fluorination.
JP2015531760A5 (enExample)
RU2014110400A (ru) Способ и промежуточные соединения для получения макролактамов
HRP20210641T1 (hr) Deuterirani heterociklični spojevi i njihova uporaba kao sredstva za kontrastiranje
RU2015113587A (ru) Амидное производное и его применение в качестве критерия стабильности фармацевтической композиции луликоназола
JP2022136074A (ja) 新規製剤及び合成方法
HRP20210183T1 (hr) 18f-obilježeni inhibitori specifičnog membranskog antigena prostate (psma) i njihova uporaba kao sredstava za vizualizaciju raka prostate
Han et al. A Protocol for the Synthesis of CF2H-Containing Pyrazolo [1, 5-c] quinazolines from 3-Ylideneoxindoles and in Situ Generated CF2HCHN2
HRP20171167T1 (hr) Priprava intermedijera pirimidina koji služe za proizvodnju macitentana
GB2519026B (en) Preparation of 18F-fluciclovine
HRP20201372T1 (hr) Radioaktivno označeni pet mglur2/3 ligandi
DK3068765T5 (en) PROCEDURE FOR FLUORING COMPOUNDS
Verbeek et al. Synthesis and preclinical evaluation of [11C] D617, a metabolite of (R)-[11C] verapamil
JPWO2011068181A1 (ja) 高速フルオロメチル化法及びそれを利用したpetトレーサーの製造方法
SI3083557T1 (en) PROCESSES FOR PREPARATION OF ESTROV 3-SUBSTITUTED (INDOL-1-IL) -OXETIC ACID
WO2008108729A1 (en) Novel 2-heteroaryl substituted indoles 695
CA2929940A1 (en) Process for fluorinating compounds
Rami-Mark et al. Synthesis, radiosynthesis and first in vitro evaluation of novel PET-tracers for the dopamine transporter:[11C] IPCIT and [18F] FE@ IPCIT
HRP20240343T1 (hr) Postupak i međuprodukt u pripravi oksetan-2-ilmetanamina
WO2014014067A1 (ja) sp3炭素のメチル化法